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Background and aims 
The global burden associated with hepatitis C virus (HCV) infection has prompted a scale-up 
of antiviral therapy. Hitherto, no data existed on the impact of scaling-up on the 
characteristics of treated populations or on sustained viral response (SVR) rates. We assessed 
the country-wide scale-up of antiviral therapy in Scotland, a country which nationally 
monitors uptake of and response to HCV treatment 
 
Methods 
Data for patients initiated on combined pegylated interferon and ribavirin therapy at 13 
specialist HCV clinics in 2001–2010 were extracted from the Scottish HCV Clinical Database 
(n=3895). Patient characteristics included age, genotype, PWID (people who inject drugs) 
status, prison referral, and diagnosed cirrhosis. Temporal trends in covariates and adjusted 
effects on SVR were examined via mixed-effects regression. 
 
Results  
The number of patients starting treatment increased from 237 in 2001-2002 to 1560 in 2009-
2010, with an increasing trend in SVR from 44% to 57% over this period. For a given clinic, 
between 2001/2 and 2010 there was a decrease in the odds of those treated being diagnosed 
cirrhotic (odds ratio[OR]=0.84 per year), and increasing temporal trends for those treated 
being PWID (OR=1.08) and prison referral (OR=1.06). Adjusting for covariates, the 
proportion of a given clinic’s patients achieving SVR was positively associated with the 
percentage PWID (OR=1.01 per percent increase; 95% confidence interval [CI]: 1.00–1.02) and 





Despite changes in patient characteristics, a country-wide scale-up of antiviral therapy did 
not compromise SVR rates. Results are highly relevant to countries planning on scaling-up 
treatment, given the forthcoming availability of new interferon-free therapies. 
 






The global public health burden associated with hepatitis C virus (HCV) infection is 
growing,[1]  with an estimated >185 million HCV antibody-positive individuals in 2005, 
relating to a global prevalence of 2.8%. [2] At the national level, disease modelling exercises 
[3-7]) suggest that HCV-related disease burden will continue to increase with current low 
rates of antiviral treatment. These models illustrate that the annual number of HCV patients 
initiated on treatment would need to be radically increased to counteract the projected rise in 
disease burden.  
 
In Scotland, a country with approximately 39,000 people currently estimated to be 
chronically infected with HCV (0.8% of the general population),[8] the annual numbers of 
patients initiated on antiviral therapy has approximately doubled between 2007/2008 (n = 
468) and 2010/2011 (n = 1049) as a result of the Scottish Government's HCV Action Plan[9] 
and significant investment.[8, 10]  This Plan aimed to ensure those infected receive optimal 
treatment, care and support, through nationally agreed guidelines, standards and targets 
and accountable national and local multi-disciplinary networks responsible for the planning, 
development and delivery of services.  A considerable emphasis was placed on co-ordination 
and monitoring to ensure progress was made. A HCV clinical database was thus established 
in almost all specialist centres delivering HCV treatment – a data-monitoring initiative 
unique to Scotland – and provided an opportunity to explore the impact of this scaling-up in 
the delivery of antiviral therapy, with respect to both the characteristics and sustained viral 
response (SVR) rates of treated patients. Data at the international level is non-existent in this 
respect, despite recent increases in the number of patients treated for HCV across parts of 
Europe, Asia, and the Middle East.[11] Moreover, it was unknown if scaling-up might have 
an associated reduction in SVR as a consequence of, for instance, specialist services being 
unable to cope with new demand and the administration of therapy to less-compliant 
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individuals. This investigation will be highly relevant and provide vital evidence for other 




We extracted the clinical treatment data for all 17 specialist clinics delivering HCV treatment 
in Scotland, over the 10-year period from the start of 2001 to the end of 2010, from the 
Scottish Hepatitis C Clinical Database held at Health Protection Scotland.[12] The patient 
population was restricted to those initiated on combined pegylated interferon and ribavirin 
(pegI&R) antiviral therapy, because we wished to distinguish any changes in SVR from 
improvements in antiviral therapy available. A total of 3,999 patients were initiated on at 
least one pegI&R treatment course within the study period.  
 
Design and variables 
Thirteen specialist clinics providing outpatient HCV treatment were included in analysis: 
Crosshouse Hospital, Dumfries & Galloway Royal Infirmary, Ninewells Hospital, Aberdeen Royal 
Infirmary, Gartnavel General Hospital (Infectious Diseases), Gartnavel General Hospital 
(Gastroenterology), Glasgow Royal Infirmary, Kirkcaldy Hospital, Monklands Hospital, Raigmore 
Hospital, Royal Infirmary Edinburgh, Southern General Hospital, and Stirling Royal Infirmary 
(total N =  3895), with four clinics (Borders General Hospital, Hairmyres Hospital, Inverclyde 
Royal Hospital, Royal Alexandra Hospital) excluded, as fewer than 50 patients in these clinics 
were initiated on treatment over the study period. Data points corresponded to clinic/year-
of-treatment-initiation combinations. Data for the first two years of the study period (2001 
and 2002) were aggregated, because there were few pegI&R treatment initiations for the 
majority of the clinics at that time. The primary outcome variable was sustained viral 
response (SVR), which was defined as a documented negative PCR test at least 6 months 
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following termination of treatment. All patients without a documented PCR test at least 6 
months following treatment termination were classified as non-SVR. Covariates of interest 
included male sex, age at treatment initiation, risk group (known PWID, known non-PWID, not 
known), referral from prison setting (yes / no), diagnosed cirrhosis (yes / no), maximum sustained 
weekly alcohol consumption (≥50 units, <50 units/week) (self-reported; set to <50 if 
unknown/not reported), and HCV genotype (2, 3 / all other genotypes). Diagnosis of 
cirrhosis was based on one or more of the following criteria: (i) clinical examination; (ii) 
radiology (i.e., ultrasound, FibroScan, computed tomography, or magnetic resonance 
imaging procedure); (iii) liver biopsy.[12] All variables were treated as cross-sectional 
variables, meaning that SVR was converted to a proportion, and all covariates except age 
were converted to percentages within each clinic–year combination; mean age was calculated 
within each clinic–year.  
 
Statistical analyses 
Analysis (a) investigated temporal trends in patients characteristics over the study period. 
Mixed-effects linear regression models were fitted separately for each covariate, with year as 
the single fixed effect (with 2001/2002 coded as 2001.5) and clinic specified as a random 
intercept, given the non-independence of observations within clinics. For analyses with a 
proportion as the response variable (i.e., all covariates except age), the logit link function was 
specified; for these models, β coefficients are interpreted as log odds ratios, so are instead 
reported as exp(β), the odds ratio. PWID was defined as the proportion of PWID risk among 
patients with known risk only (i.e. patients with the status not known were excluded). 
 
Analysis (b) describes temporal trends in SVR over the study period, by fitting a mixed-
effects linear regression model with year as the single fixed effect and clinic as a random 
intercept. A comparable analysis was also conducted on the study population excluding 
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patients with diagnosed cirrhosis. 
 
In analysis (c), we fitted time-series cross-sectional (TSCS) regression models appropriate for 
our data; these models can specify grouping variables as fixed or random effects. We 
attempted to isolate any unique effects on SVR that were associated with changing patient 
characteristics due to broadening of the eligible treatment patient population (e.g., the 
percentage of PWID patients, the percentage of referrals from prison settings) over the study 
period, by adjusting for other covariates. A Hausman test was conducted to assess the 
appropriateness of specifying clinic as a random effect rather than a fixed effect, and the need 
to include year as an additional fixed effect was assessed using a Lagrange multiplier test. In 
this type of regression model, a single regression coefficient fitted for a given covariate (e.g., 
PWID) aggregates both between-clinic and within-clinic effects (i.e., time-invariant and time-
varying components of the covariate effect).[13] Therefore, a test for equality of these 
parameters was conducted before final model specification,[13, 14]  and if necessary, 
separate covariates were fitted in the final model instead: the cluster mean (x
j
), representing 




), representing the 
within-clinic, or temporal, effect.  
 
To compare covariate effects obtained with analysis of the TSCS view of the data, we also 
conducted an individual-level analysis by fitting a multifactorial random-effects binomial 
regression model to the same dataset. Risk group was necessarily fitted as a categorical 
variable (known PWID, known non-PWID, not known). Note that the individual-level approach 
does not allow the main research question to be addressed (i.e., investigation of the 
associations of changing clinic patient characteristics over time with [changes in] SVR rates 




All regression models were fitted using the lme4[15] and plm[16] packages for the R 




Figure 1 illustrates the growth of the treated population over the study period, showing both 
the cumulative numbers of patients initiated on pegI&R treatment and the cumulative 
number of SVR achieved, in 17 Scottish specialist clinics over the period 2001-2010. Table 1 
summarises the characteristics of our study population according to calendar year period of 
initiation on antiviral therapy. There was an increase in the overall number of patients 
starting treatment over time (see also Fig. 1), from 237 in 2001-2002 to 1560 in 2009-2010. The 
number of treated patients achieving an SVR also increased from 104 (44%) in 2001-2002 to 
882 (57%) in 2009-2010; excluding those patients with diagnosed cirrhosis, SVR increased 
from 51% in 2001-2002 to 59% in 2009-2010. Over the same period, the proportion of treated 
patients with known risk group that were current/former PWID increased from 112/212 
(53%) to 1023/1351 (76%), and the proportion with diagnosed cirrhosis decreased from 30% 
to 11%. The average age at treatment initiation was 41 years (SD = 9.5 years), which was 
stable across time.   
 
Trends over time (analysis (a)) for the principal covariates are displayed in Figure 2, in which 
data are grouped according to clinic and calendar year of treatment initiation (which may 
differ from calendar year of SVR if therapy was begun later in the year). Between 2001/2 and 
2010, there was a statistically significant decreasing trend observed for the within-clinic 
proportion of treated patients with diagnosed cirrhosis (OR = 0.84, p < 0.0001; i.e. there was a 
16% decrease in the odds of a treated patient having diagnosed cirrhosis). Significant 
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increasing temporal trends were found for the within-clinic proportion of treated patients 
with PWID risk (OR=1.08, p = 0.026) and prison referral (OR = 1.06, p = 0.002). In the last year 
of the study period, an across-clinic mean of 57%, 11%, 77% and 6.7% treated patients were 
HCV genotype 2 or 3, had diagnosed cirrhosis, were current/former PWID, or were referred 
from a prison setting, respectively. 
 
The SVR temporal trend (analysis (b)) for individual clinics, and the trend of the mean over 
all clinics, is displayed in Fig. 3. At the clinic level, there was a non-significant overall 
increasing trend in the proportion of treated patients achieving SVR over the study period 
(odds ratio [OR] per year = 1.03, p = 0.33; in other words, a 3% increase in the odds of 
achieving SVR per year), from an across-clinic mean of 44% in 2001/2002 to 56% in 2010. 
Stratified analyses conducted according to genotype (i.e., separately for genotype 2/3 and for 
other genotypes) indicated similar SVR temporal trends (Fig. 3). A supplementary analysis 
(Appendix, Table A2 and Fig. A2) conducted on only those patients without diagnosed 
cirrhosis (n=3297) also did not indicate any trend in the proportion achieving SVR, from 
across-clinic mean of 51% in 2001/2 to 58% in 2010 (OR = 0.97, p = 0.38). Note that the lines 
indicating across-clinic means in these SVR plots do not show variability, and thus only 
serve to visually indicate temporal trends. 
 
The covariates of interest are all plausibly associated with SVR, but apparent crude 
associations between a temporal trend in SVR and a trend in a particular covariate may be 
confounded by other, related variables. Therefore, we also estimated the associations 
between within-clinic proportions achieving SVR and within-clinic patient characteristics 
after adjusting for other covariates (analysis (c)). Male sex and weekly alcohol consumption were 
excluded from the adjusted model, as no crude association was observed with SVR. Based on 
the Hausman test result, clinic was specified as a random effect. The final fitted mixed-effects 
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Adjusting for the other covariates, there was a significant 1.027-fold increase in the odds of 
SVR (95% CI: 1.016-1.037) with every percentage increase in HCV genotype 2/3 patients 
treated over time (Table 2). For a given clinic, there was a statistically significant 1.012-fold 
increased odds of SVR with every percentage increase in PWID treated over time.  
  
In individual-level analyses (Appendix, Table A1), there was a statistically significant 
decreased odds of SVR for a patient associated with each 1-year increase in their age (OR = 
0.977; i.e. a 2.3% decrease in the odds of SVR per year of age), and a significant decreased 
odds of SVR with diagnosed cirrhosis (OR = 0.26, which is equivalent to OR=0.987 per 
percentage decrease, to allow easy comparison with the TSCS results, in which cirrhosis is a 
proportion rather than a binary variable). The individual-level analysis also indicated 
decreased odds of SVR for PWID compared with non-PWID risk (OR = 0.82), and increased 
odds of SVR for genotype 2/3 compared with other genotypes (OR=2.77). 
 
DISCUSSION 
The current study represents the first evidence investigating temporal trends in response to 
HCV antiviral therapy. Despite a country-wide scale-up of chronic HCV-infected patients 
initiated on pegI&R antiviral therapy over the study period – from 237 patients in 2001-2002 
to 1560 in 2009-2010 – and changes in patient characteristics over the same period –  SVR 
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rates were not compromised. Temporal trends in several patient characteristics known to be 
associated with SVR rates[12]  were found; namely, within clinics there were increased odds 
of treated patients with PWID status and referred from prison settings, and decreased odds 
of treated patients with diagnosed cirrhosis, but there was no evidence that the proportion of 
patients achieving an SVR was affected. There was also no evidence that the greater 
proportion of diagnosed cirrhotic patients treated in the earlier part of the study period 
concealed a downward trend in SVR rates, as excluding these patients from analysis did not 
change the results. 
 
Our main finding authenticates the assumption – of SVR rates being maintained, despite the 
broadening of the treated patient base –  employed in numerous modelling studies (recently 
those reported in [18, 19]) predicting the impact of scaling-up therapy.  
 
For a given clinic, a higher proportion of SVR was associated with genotype 2/3 HCV 
compared with all other genotypes (adjusting for other covariates), which is consistent with 
previous studies.[12, 20-22]  Both the unadjusted and adjusted TSCS analysis indicated a 
positive association between SVR and the proportion of patients who were current or former 
PWID, which was unexpected. This cannot be interpreted as a causal association (e.g., more 
PWID initiated on treatment gives rise to a greater SVR rate), because a single regression 
coefficient in the TSCS analysis aggregates time-invariant and time-varying components of 
the covariate effect. That is, a greater proportion of PWID may be treated within clinics that 
have better overall SVR rates than within clinics with lower rates.[14] Because the individual-
level analysis indicated that PWID risk was associated with a significantly decreased odds of 
achieving an SVR (OR=0.82, where non-PWID risk was the reference group), PWID is likely 
confounded with age and being diagnosed with cirrhosis in the TSCS analysis. Clinics that 
treat younger patients and/or a smaller proportion of patients with diagnosed cirrhosis will 
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tend to have better clinic-level SVR rates, all else being equal. Because PWID tend to be 
younger and have less progressed liver disease, including PWID in the adjusted model tends 
to conceal the effects of age and diagnosed cirrhosis, indicated by the change in regression 
coefficient from <1 (unadjusted) to >1 (adjusted).  
 
In the context of a continuing rising trend in annual number of HCV infected persons 
developing and dying from end-stage liver disease (ESLD) in Scotland,[8]  the finding of a 
significant decrease in the odds of those treated being diagnosed with cirrhosis over time is 
concerning. To curb the ongoing rise in ESLD in the short term, treatment of those with more 
advanced disease is necessary. The absolute number of diagnosed cirrhosis patients of course 
still increased over time (doubling between 2001–2 and 2009–10); but not to the same extent 
as the overall number treated (with an almost seven-fold rise between 2001–2 and 2009–10) 
and the number of PWID treated (with a nine-fold rise between 2001–2 and 2009–10). The 
expansion of treatment among PWID relates to the Scottish Government's HCV Action Plan 
and initiatives to increase diagnosis and treatment particularly among this group, with the 
introduction of dried blood spot testing in specialist addiction services.[23]  As liver biopsy 
was one of the diagnostic criteria for cirrhosis, the declining odds of treated patients being 
diagnosed cirrhotic could have been exaggerated due to the change in biopsy practice – the 
biopsy rate dropped from 14% in 2000–2004 to 3% in 2005–2010 – and so the prevalence of 
cirrhosis among our patients may have been under-estimated to a greater extent in recent 
years. However, from another study which examined FibroScan data, we estimated that 15% 
of patients treated for HCV in Scotland during 2009-2013 were cirrhotic [H. Innes, pers. 
comm.], which is only slightly higher than that observed here for patients treated during 
2009–2010 (10%).  Thus, our findings still suggest that greater effort is needed to identify and 




We restricted the dataset to treatment initiations on pegI&R; otherwise, we could not 
distinguish a possible rising trend in SVR rates from improvements in antiviral therapy 
during the same period. However, the proportion achieving a SVR was quite stable over the 
study period. Another limitation is the paucity of data in the earliest years of the study 
period. In 2001-2, there was an average of 14 patients per clinic initiated on antiviral therapy; 
therefore the clinic-specific covariate estimates in the early part of the study period will not 
be as stable as estimates for later years. 
 
Our intention-to-treat analysis, while appropriate for the research questions, also means that 
SVR proportions are lower than if we had excluded patients without PCR test results 
following the end of treatment (n=134; 3.4%) or persons otherwise lost to follow-up from the 
denominator. This would slightly restrict the variability in SVR across clinics and over time, 
weakening the strength of possible associations with the covariates of interest. 
 
Finally, because active injecting status is not recorded in the Scottish Hepatitis C Clinical 
database, we were unable to determine whether the rising trend observed in the proportion 
of treatment patients who are PWID (i.e., those either currently or formerly injecting drugs) 
also applies to those who were actively injecting drugs. It may be that increasing numbers of 
relatively stable patients with a past history of injecting drug use and with mild disease were 
initiated on treatment, possibly as a consequence of the Scottish Government's HCV Action 
Plan.[9] If younger PWID (i.e.,. <35 years of age) are taken as a proxy for active injectors, 
then a rising trend in this group is still apparent (data not shown). The role of antiviral 
therapy in reducing transmission among PWID has been previously highlighted in 
modelling studies,[24] and there is accumulating evidence that the scale-up of interventions 
among those who actively inject in Scotland – principally injecting equipment provision and 
opiate substitute therapy, but potentially also antiviral therapy – has lead to a reduction in 
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the incidence of HCV infection.[25-27] 
 
 
Antiviral treatment uptake remains low internationally; with <5% of chronically infected 
patients treated per year across most of Europe,[28]  Australia,[29] and USA.[30]  There are 
however promising new interferon-free therapies forthcoming: so called direct-acting 
antivirals (DAA), which should allow much higher SVR rates to be achieved, even among 
those with cirrhosis.[31, 32] The availability of these new effective treatments will mean that 
countries will be looking at scaling-up therapy delivery at the national level. In Scotland, the 
scale-up in treatment uptake was achieved[10] by a combination of major investment (43 
million pounds during 2008/09 to 2010/11), the development of national guidelines and 
targets for clinical services, affiliation of NHS boards to multi-disciplinary managed HCV 
care networks and appointment of HCV executive and clinical leads accountable for local 
performance, among other initiatives such as awareness-raising campaigns and the national 
procurement of antiviral drugs.[23] 
 
Although published data on the impact of treatment scale-up on SVR rates in other countries 
are scarce, success (in terms of treatment uptake) is notable for France, who have had a 
National Plan for Hepatitis B and C in place since 1999.[33] France achieved a treatment rate 
of 16% in 2005, and a reported 10,000 patients were initiated on antiviral therapy in 2011.[34] 
Common to both National strategies in France and Scotland has been a robust evidence base 
and reliable epidemiological data to drive policy, with quantifiable goals providing 
important motivation for success.[35] 
 
In summary, the comprehensiveness of Scotland's clinical treatment database has provided a 
unique opportunity to investigate the impact on SVR rates of broadening treatment to those 
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patient groups who are often ineligible for clinical trials (e.g., PWID, incarcerated 
individuals), but nevertheless account for the majority of the chronically infected population. 
SVR rates did not appear to be compromised, despite the broadening of the eligible patient 
base associated with the implementation of the HCV Action Plan and other initiatives. 
Monitoring the characteristics of treated patients will be vitally important over the coming 
years to ensure that the patients who receive treatment are those who are most in need. The 
present results are highly relevant to countries planning on scaling-up treatment, given the 
forthcoming availability of new interferon-free therapies. 
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Table 1.  Characteristics of the individuals in the study population, by data collection period 
of pegI&R treatment initiation. 
 
 2001-2 2003-4 2005-6 2007-8 2009-10 All years 
 N (col %) N (col %) N (col %) N (col %) N (col %) N (col %) 
All patients 237 – 496 – 696 – 906 – 1560 – 3895 – 
Mean N per 18 [2-55] 38 [10-96] 54 [7-138] 70 [15-139] 120 [9-258] 235 [8-564] 
clinic [range] 
Male 179 (76) 351 (71) 491 (71) 633 (70) 1163 (75) 2817 (72) 
M age (SD) 43 (9.3) 42 (9.4) 41 (9.4) 42 (9.6) 41 (9.5) 41 (9.5) 
Diagnosed 72 (30) 119 (24) 119 (17) 124 (14) 164 (11) 598 (15) 
  cirrhosis 
Genotype 2/3 114 (48) 280 (57) 446 (64) 511 (56) 889 (57) 2240 (58) 
Alcohol >50 43 (18) 107 (22) 159 (23) 202 (22) 317 (20) 828 (21) 
Risk group 
 Non-PWID 100 (42) 168 (34) 230 (33) 259 (29) 328 (21) 1085 (28) 
 PWID 112 (47) 274 (55) 399 (57) 533 (59) 1023 (66) 2341 (60) 
 Not known 25 (11) 54 (11) 67 (10) 114 (13) 209 (13) 469 (12) 
Prison 3 (1) 14 (3) 37 (5) 43 (5) 117 (8) 214 (5) 
  referral 
SVR  
   All patients 104 (44) 256 (52) 415 (60) 491 (54) 882 (57) 2148 (55) 
   Excl. cirrhotic 84 (51) 224 (59) 384 (67) 464 (59) 823 (59) 1979 (60)  
 
Note: M = mean; N = number of patients; col % = column percentage; SD = standard deviation; PWID 
= people who inject drugs; Alcohol >50 = maximum sustained alcohol use greater than 50 units/week. 
Excl. cirrhotic = study population excluding patients who had been diagnosed with cirrhosis.  
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Table 2.  Odds-ratio transformed coefficients from the final fitted mixed-effects (adjusted) 
regression model; the dependent variable is logit-transformed proportion SVR at the clinic 
level (analysis (c)). Unadjusted ORs are also shown. 
 
 Unadjusted Adjusted  
Variable OR (95% CI) OR (95% CI) 
Intercept   – – 0.024 (0.002 – 0.323) – 
Age (per year) 0.971 (0.925 – 1.019) 1.031 (0.980 – 1.085) 
Diagnosed cirrhosis 0.997  (0.987 – 1.008) 1.005 (0.996 – 1.017) 
Genotype 2 or 3 1.024 (1.014 – 1.034) 1.027 (1.016 – 1.037) 
PWID  1.009 (1.001 – 1.018) 1.012 (1.004 – 1.021) 
Prison referral 1.020 (1.000 – 1.040) 1.010 (0.992 – 1.029)  
 







Fig. 1. Cumulative number of pegylated interferon & ribavirin treatment initiations (filled 
circles) and SVRs (squares)  in Scottish specialist hepatitis clinics by calendar year of 
treatment initiation (analysis (a)). The cumulative number of non-SVRs is the difference 
between green and red series.  
 
Fig. 2. Spaghetti plots of six covariates over the study period (2001/2002 to 2010), analysis 
(a). Individual panels show mean age, percent diagnosed cirrhosis, percent maximum 
sustained alcohol consumption ≥50 units/week, percent genotype 2/3, percent PWID, and 
percent prison referral. Individual clinics are indicated with grey lines; the across-clinic mean 
is indicated with a weighted black line. 
 
Fig. 3. SVR over the study period (2001/2 to 2010). Panel A shows SVR stratified by 
genotype category. Panel B is a spaghetti plot of SVR over the study period, analysis (b), 
where individual clinics are indicated with grey lines and the across-clinic mean is indicated 







Table A1.  Odds-ratio transformed coefficients from unadjusted and adjusted mixed-effects 
logistic regression analysis of individual-level data; the dependent variable is SVR. 
 
 Unadjusted Adjusted 
Variable OR (95% CI)  OR (95% CI)  
Intercept  –   2.39 (1.56 – 3.65) 
Age (per year)  0.97  (0.96 – 0.97)  0.98 (0.97 – 0.98)   
Diagnosed cirrhosis 0.24 (0.20 – 0.29)  0.26 (0.21 –0.32)   
Genotype 2 or 3 2.74 (2.40 – 3.12)  2.77 (2.41 – 3.17)   
Risk group Non-PWID Ref.   Ref. 
 PWID 0.94 (0.81 – 1.09)  0.82 (0.70 – 0.96) 
 Not known 1.01 (0.81 – 1.27 )  0.92 (0.73 – 1.17)  
Prison referral  0.96 (0.96 – 1.30)  0.89 (0.64 – 1.23)   
 





Fig. A1. SVR over the study period (2001/2 to 2010), stratified by genotype category and risk 




Table A2.  Odds-ratio transformed coefficients from fitted mixed-effects regression models 
applied to the study population without diagnosed cirrhosis (n=3297); the dependent 
variable is logit-transformed proportion SVR at the clinic level. 
 
 Unadjusted Adjusted  
Variable OR (95% CI) OR (95% CI) 
Intercept   – – 0.099 (0.005 – 1.850) – 
Age (per year) 0.988 (0.938 – 1.041) 1.011 (0.954 – 1.071) 
Genotype 2 or 3 1.021 (1.019 – 1.032) 1.032 (1.019 – 1.044) 
PWID  1.008 (0.998 – 1.019) 1.006 (0.997 – 1.017) 
Prison referral 1.001 (0.977 – 1.026) 0.995 (0.975 – 1.015)  
 




Fig. A2. Spaghetti plot of SVR over the study period (2001/2 to 2010) for the study 
population without diagnosed cirrhosis. Individual clinics are indicated with grey lines; the 
across-clinic mean is indicated with a weighted black line. 
 
 
 
 
 
 
